Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2-p53 Inhibitor in Clinical Development.
Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M.D., Beck, H.P., Canon, J., Chen, A., Chen, X., Chow, D., Deignan, J., Duquette, J., Eksterowicz, J., Fisher, B., Fox, B.M., Fu, J., Gonzalez, A.Z., Gonzalez-Lopez De Turiso, F., Houze, J.B., Huang, X., Jiang, M., Jin, L., Kayser, F., Liu, J.J., Lo, M.C., Long, A.M., Lucas, B., McGee, L.R., McIntosh, J., Mihalic, J., Oliner, J.D., Osgood, T., Peterson, M.L., Roveto, P., Saiki, A.Y., Shaffer, P., Toteva, M., Wang, Y., Wang, Y.C., Wortman, S., Yakowec, P., Yan, X., Ye, Q., Yu, D., Yu, M., Zhao, X., Zhou, J., Zhu, J., Olson, S.H., Medina, J.C.
J.Med.Chem.